Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

by San-Miguel, Jesus , Cavo, Michele , Crist, Wendy , Crepaldi, Andre , Grosicki, Sebastian , Shelekhova, Tatiana , Qi, Ming , Lucio, Paulo , Liberati, Anna M , Wang, Jianping , Deraedt, William , Garg, Mamta , Chiu, Christopher , Iosava, Genadi , Dimopoulos, Meletios A , Jakubowiak, Andrzej , Doyen, Chantal , Mateos, María-Victoria , Campbell, Philip , Knop, Stefan , Nagy, Zsolt , Fujisaki, Tomoaki , Cook, Mark , Suzuki, Kenshi , Carson, Robin , Nguyen, Huong , Kaplan, Polina , Pour, Ludek , Yoon, Sung-Soo

in Autografts / Bortezomib / Cancer therapies / Clinical trials / Drug dosages / Drug therapy / Immunotherapy / Inhibitor drugs / Leukocytes / Medical prognosis / Melphalan / Minimal residual disease / Monoclonal antibodies / Multiple myeloma / Neutropenia / Prednisone / Risk assessment / Stem cell transplantation / Targeted cancer therapy / Thrombocytopenia

2018

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

2018

Confirm

Do you wish to request the book?

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

2018

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

San-Miguel, Jesus,

Cavo, Michele,

Crist, Wendy,

Crepaldi, Andre,

Grosicki, Sebastian,

Shelekhova, Tatiana,

Qi, Ming,

Lucio, Paulo,

Liberati, Anna M,

Wang, Jianping,

Deraedt, William,

Garg, Mamta,

Chiu, Christopher,

Iosava, Genadi,

Dimopoulos, Meletios A,

Jakubowiak, Andrzej,

Doyen, Chantal,

Mateos, María-Victoria,

Campbell, Philip,

Knop, Stefan,

Nagy, Zsolt,

Fujisaki, Tomoaki,

Cook, Mark,

Suzuki, Kenshi,

Carson, Robin,

Nguyen, Huong,

Kaplan, Polina,

Pour, Ludek,

Yoon, Sung-Soo

2018

Overview

In patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, the addition of daratumumab to bortezomib, melphalan, and prednisone increased progression-free survival and the response rate at the cost of an increase in infections.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject